Development of a biotechnology process for the production of a novel hyperglycosylated long‐acting recombinant bovine follicle‐stimulating hormone

Follicle‐stimulating hormone (FSH) is an important protein used for bovine ovarian hyperstimulation in multiple ovulation and embryo transfer technology (MOET). Several attempts to produce bovine FSH (bFSH) in recombinant systems have been reported, nonetheless, up to date, the most commonly used products are partially purified preparations derived from porcine or ovine (pFSH or oFSH) pituitaries. Here we describe the development of a biotechnology process to produce a novel, hyperglycosylated, long‐acting recombinant bFSH (LA‐rbFSH) by fusing copies of a highly O‐glycosylated peptide. LA‐rbFSH and a nonmodified version (rbFSH) were produced in suspension CHO cell cultures and purified by IMAC with high purity levels (>99%). LA‐rbFSH presented a higher glycosylation degree and sialic acid content than rbFSH. It also demonstrated a notable improvement in pharmacokinetic properties after administration to rats, including a higher concentration in plasma and a significant (seven‐fold) reduction in apparent clearance (CLapp). In addition, the in vivo specific bioactivity of LA‐rbFSH in rats was 2.4‐fold higher compared to rbFSH. These results postulate this new molecule as an attractive substitute for commercially available porcine pituitary‐derived products. Graphical and Lay Summary Production of a new hyperglycosylated long‐acting recombinant bovine follicle‐stimulating hormone by fusing a highly O‐glycosylated peptide. This novel hormone offers improved pharmacokinetics and biopotency, becoming an attractive alternative to porcine‐derived products in bovine reproductive technology.